Wright Medical Group N.V

Wright Medical — Merger or Acquisition (October 2014)

23 slides from Wright Medical's merger presentation, Oct 28, 2014

  1. Slide 1: Employee Town Hall

    Filed by Wright Medical Group, Inc. pursuant to Rule to Rule 425 Under the Securities Act of 1933 Deemed filed pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Wright Medical Group, Inc. Commission File No. 001-35823 Employee Town Hall October 28, 2014 CONTENTS ARE

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of

  3. Slide 3: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures Wright and Tornier use non-GAAP financial measures, including EBITDA, as adjusted. Their respective management teams believe that the presentation of these measures provides useful information to investors and that these measures may assist investors in evaluating

  4. Slide 4: Additional Information And Where To Find It

    Additional Information And Where To Find It In connection with the proposed merger, Tornier plans to file with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 that will include a joint proxy statement of Wright and Tornier that also constitutes a prospectus of

  5. Slide 5: Agenda

    Agenda • Yesterday’s Announcements • Who Is Tornier? • Why this combination? • What happens after today? • How are we planning for the future? • Leadership’s commitment to you • Conclusion & Summary • Q&A CONTENTS ARE CONFIDENTIAL 5

  6. Slide 6: Augment is approvable for ankle and/or hindfoot fusion indications!!!

    Augment is approvable for ankle and/or hindfoot fusion indications!!! CONTENTS ARE CONFIDENTIAL 6

  7. Slide 7: Augment Bone Graft is approvable for ankle and/or hindfoot fusion indications

    Augment ® Bone Graft is approvable for ankle and/or hindfoot fusion indications • Approvable letter indicates that FDA determined Augment ® Bone Graft to be safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications • Final approval subject to customary preapprova

  8. Slide 8: A Breakthrough Biologic!

    A Breakthrough Biologic! Unique solution for Platform for future Breakthrough ankle and/or hindfoot growth opportunities biologic • Further accelerate • Nothing else like it • Bone repair, soft growth on the market tissue indications CONTENTS ARE CONFIDENTIAL 8

  9. Slide 9: Challenging Third Quarter

    Challenging Third Quarter • Revenue fell short of expectations – Net sales for Q3: $71.3 million – up 24% vs. last year • Normalizing for acquisitions, up 8% vs. last year – Total ankle sales growth of 25% • Slower growth rate than anticipated in our U.S. business – Increasing focus on core products

  10. Slide 10: Yesterday's Announcement to Combine

    Yesterday’s Announcement to Combine Generate long-term value for our customers, employees, and shareholders THE Premier Global Extremities-Biologics Company Comprehensive Upper & Lower Extremity Product Portfolio Accelerated Opportunities to Grow FASTER Lower, Upper, & Bio – Three of Highest Growth

  11. Slide 11: Important notes on the Announcement

    Important notes on the Announcement Excitement Wright & Tornier leaders thrilled – once in a life time about the Deal opportunity and very bright future! Wright Medical Group N.V. – led by Bob Palmisano as CEO Familiar Name and Tornier’s Dave Mowry as COO and Leadership Pascal will continue to serve

  12. Slide 12: Where We Will Operate

    Where We Will Operate Memphis: U.S. Headquarters Wright Operations Center: Arlington Staying in Lower Extremity and Biologics U.S. HQ: Memphis Augment Tennessee team continue to be based in Franklin Upper Extremity U.S. HQ: Tornier’s Minnesota facility Incorporated in The Netherlands Cherry Road nd

  13. Slide 13: Tornier at a Glance

    Tornier at a Glance Company Summary Recent Strategic Initiatives • Extremities company with leadership position in • Transitioned US Sales organization into separate Upper Extremities -- shoulder dedicated Upper and dedicated Lower Extremity • NASDAQ: TRNX www.tornier.com reps, including a significa

  14. Slide 14: Summing Up: Compelling Strategic Rationale

    Summing Up: Compelling Strategic Rationale THE Premier High-Growth Extremities-Biologics Company Uniquely positioned in fastest growth areas of orthopaedics Three cornerstones: Total Ankle, Shoulder Replacement, Biologics Leading technologies & specialized sales forces addressing continuum of care t

  15. Slide 15: Comprehensive Upper & Lower Extremity Product Portfolio

    Comprehensive Upper & Lower Extremity Product Portfolio UPPER EXTREMITIES LOWER EXTREMITIES ~10% of Revenue 59% of Revenue ~62% of Revenue 19% of Revenue *2013 revenue BIOLOGICS CONTENTS ARE CONFIDENTIAL 15

  16. Slide 16: We speak a common language

    We speak a common language CONTENTS ARE CONFIDENTIAL 16

  17. Slide 17: We can achieve more as one company!

    We can achieve more as one company! EMPLOYEES Larger, dynamic organization enhances career growth opportunities CUSTOMERS Combined products, sales, distribution, medical education and relationships expands our reach PATIENTS Dedicated R&D will power innovation across combined portfolio to enhance ou

  18. Slide 18: What does this mean for employees TODAY?

    What does this mean for employees TODAY? Close in 2015: Deal is expected to close in the first half of 2015 and will require regulatory and shareholder approvals • Business as Usual: Customer Service is our Number One Priority • Execute on operational objectives and individual goals • No Immediate C

  19. Slide 19: How are we planning for the integration?

    How are we planning for the integration? • Significant Resources Dedicated to the Combination that will: Identify best practices to leverage combined strengths, maximize growth and deliver best-in-class service Reposition and align strategic vision for both entities and prepare for a successful “Day

  20. Slide 20: Synergies and Timing

    Synergies and Timing • We expect to realize cost synergies totaling $40 million to $45 million from the following areas – some examples: – Multiple ERP systems – Tornier outsources most of its foot and ankle manufacturing – we have a world class manufacturing facility – We can eliminate duplicate pu

  21. Slide 21: Commitment to open & transparent communication

    Commitment to open & transparent communication • Future opportunity to meet with Tornier leadership • We will provide ongoing, frequent and timely updates: – In-person, department meetings – Written communication – Human Resources office hours – Management team is dedicated to obtaining answers to y

  22. Slide 22: A bright & exciting future as new Wright Medical!

    A bright & exciting future as new Wright Medical! Premier High- Accelerated Growth Significant Scale Growth Extremities- Opportunities and Scope Biologics Company Better Serves Customers Increases Employee Development Opportunities Satisfies Shareholders CONTENTS ARE CONFIDENTIAL 22

  23. Slide 23: Q&A

    Q&A CONTENTS ARE CONFIDENTIAL

Wright Medical Group — Merger or Acquisition (October 2014) on 6ix